InspireMD, Inc.
NSPRNasdaq
$0.70
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↓ -70.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$58.8M
Enterprise Value
$17.2M
P/E
—
P/S
5.4
P/B
1.3
EV/EBITDA
0.0
PEG
—
FCF Yield
-68.3%
Dividend Yield
—
Revenue (TTM)
$10.8M
Net Income (TTM)
-$51.3M
Free Cash Flow (TTM)
-$40.1M
Gross Margin
28.1%
Operating Margin
-480.6%
Net Margin
-473.0%
ROE
-117.6%
ROIC
-2011.9%
Debt / Equity
—
Net Cash
$41.6M
Return 1Y
-70.9%
Company profile
InspireMD, Inc. focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company sells its products through local distributors.
- CEO
- Marvin L. Slosman
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 50
- Headquarters
- Florida
- Website
- inspiremd.com
Management & directors
- Slosman MarvinCEO and President
- Gleason Shane ThomasChief Commercial Officer
- Lawless Michael AChief Financial Officer
- Tommasoli AndreaChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
NSPR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.4M↑ +122.2%
Diluted EPS-$0.16↓ -172.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $4.5M | $5.2M | $6.2M | $7.0M | $9.0M |
| Gross profit | $83,000.00 | $754,000.00 | $1.1M | $1.8M | $1.5M | $2.6M |
| Operating income | -$10.4M | -$14.7M | -$18.7M | -$21.1M | -$33.5M | -$49.6M |
| Net income | -$10.5M | -$14.9M | -$18.5M | -$19.9M | -$32.0M | -$48.8M |
| Diluted EPS | — | — | -$2.35 | -$0.82 | -$0.76 | -$0.76 |
| Operating cash flow | -$9.1M | -$13.2M | -$15.5M | -$16.4M | -$21.9M | -$35.1M |
| Free cash flow | -$9.2M | -$13.6M | -$16.0M | -$16.8M | -$23.3M | -$36.8M |
| Gross margin | 3.3% | 16.8% | 21.6% | 29.1% | 21.5% | 29.5% |
| Operating margin | -417.7% | -327.4% | -361.9% | -340.7% | -478.0% | -552.6% |
| Net margin | -424.3% | -331.9% | -357.6% | -321.0% | -456.6% | -543.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.8M | $1.9M | $1.5M | $1.8M | $2.5M | $3.1M | $3.4M |
| Gross profit | $331,000.00 | $414,000.00 | $469,000.00 | $292,000.00 | $313,000.00 | $864,000.00 | $1.2M | $687,000.00 |
| Operating income | -$8.3M | -$8.5M | -$9.4M | -$11.5M | -$13.0M | -$13.1M | -$12.1M | -$14.0M |
| Net income | -$7.9M | -$7.9M | -$9.2M | -$11.2M | -$13.2M | -$12.7M | -$11.8M | -$13.7M |
| Diluted EPS | -$0.22 | -$0.16 | -$0.17 | $0.22 | -$0.26 | -$0.17 | -$0.55 | -$0.16 |
| Operating cash flow | -$4.4M | -$5.7M | -$6.8M | -$8.8M | -$8.3M | -$8.6M | -$9.3M | -$12.3M |
| Free cash flow | -$4.8M | -$6.1M | -$7.1M | -$9.2M | -$8.9M | -$9.0M | -$9.7M | -$12.5M |
| Gross margin | 19.0% | 22.9% | 24.1% | 19.1% | 17.6% | 34.2% | 37.5% | 20.2% |
| Operating margin | -475.0% | -467.5% | -480.6% | -749.5% | -732.2% | -517.3% | -383.7% | -411.4% |
| Net margin | -454.8% | -435.9% | -470.7% | -730.3% | -739.7% | -503.7% | -373.5% | -402.9% |
Company news
Jun 16, 2026
Jun 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | Stuka Paul | Buy | 20,000 | $0.88 | $17,500.00 | filing |
| 2026-05-14 | Stuka Paul | Buy | 5,000 | $1.15 | $5,750.00 | filing |
| 2026-05-13 | Stuka Paul | Buy | 10,000 | $1.16 | $11,575.00 | filing |
| 2026-05-12 | Slosman Marvin· CEO and President | Buy | 21,000 | $1.20 | $25,200.00 | filing |
| 2026-05-11 | Stuka Paul | Buy | 10,000 | $1.19 | $11,900.00 | filing |
| 2026-05-11 | Stuka Paul | Buy | 10,000 | $1.19 | $11,900.00 | filing |
| 2026-05-08 | Stuka Paul | Buy | 65,626 | $1.16 | $76,126.16 | filing |
| 2026-05-08 | Stuka Paul | Buy | 65,626 | $1.16 | $76,126.16 | filing |
| 2026-05-07 | ROUBIN GARY S | Buy | 90,000 | $1.18 | $106,200.00 | filing |
| 2026-05-07 | Ward Scott R. | Buy | 73,255 | $1.15 | $84,243.25 | filing |
| 2026-05-07 | Stuka Paul | Buy | 6,378 | $1.15 | $7,334.70 | filing |
| 2026-05-06 | Ward Scott R. | Buy | 15,995 | $1.15 | $18,394.25 | filing |
| 2026-05-06 | Stuka Paul | Buy | 1,517 | $1.12 | $1,699.04 | filing |
| 2026-02-02 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 2,000 | $1.60 | $3,208.00 | filing |
| 2026-01-30 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 2,900 | $1.63 | $4,729.90 | filing |
| 2026-01-29 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 5,000 | $1.65 | $8,250.00 | filing |
| 2026-01-28 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 12,395 | $1.65 | $20,464.15 | filing |
| 2026-01-27 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 4,781 | $1.66 | $7,955.58 | filing |
| 2026-01-22 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 8,411 | $1.57 | $13,238.91 | filing |
| 2026-01-21 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 17,593 | $1.62 | $28,553.44 | filing |
| 2026-01-20 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 2,955 | $1.59 | $4,710.27 | filing |
| 2026-01-16 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 2,250 | $1.61 | $3,627.00 | filing |
| 2026-01-15 | Gleason Shane Thomas· Chief Commercial Officer | Sale | 2,909 | $1.58 | $4,593.31 | filing |
| 2026-01-14 | Dearen Danny L. | Award | 44,030 | $0.00 | $0.00 | filing |
| 2026-01-14 | Ward Scott R. | Award | 88,053 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.